Giuliana Autiero

Giuliana Autiero

Auto-generated profile, based on publicly available information

Giuliana Autiero

Department of Precision Medicine University of Campania “Luigi Vanvitelli” Napoli Italy

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2024 in Vasa
Verified
Journal Article
Closed access
MVMichele Dalla Vestra
Michele Dalla Vestra
MZMarta Zanon
Marta Zanon
EGElisabetta Grolla
Elisabetta Grolla
ATAndrea Tavernese
Andrea Tavernese
GAGiuliana Autiero
Giuliana Autiero
FPFabio Presotto
Fabio Presotto

25 July 2025 in Clinical Transplantation
Verified
Journal Article
Open access
FPFabian Patauner
Fabian Patauner
FBFilomena Boccia
Filomena Boccia
SMSilvia Masini
Silvia Masini
GAGiuliana Autiero
Giuliana Autiero
RGRaffaella Gallo
Raffaella Gallo
Emanuele Durante-MangoniEmanuele Durante-Mangoni
Emanuele Durante-Mangoni
Cancer is among the major causes of death after heart transplant (HTx). Risk factors for cancer occurrence in this setting are not well established. This was a retrospective observational study of patients who underwent HTx between 2006 and 2019 and were followed up until May 2024. Clinical variables possibly associated with cancer were assessed with univariable and multivariable analyses. Survival analysis was carried out drawing Kaplan Meier curves and a Cox regression with time‐varying covariates were performed to overcome the immortal‐time‐bias. Three‐hundred‐thirty‐five HTx recipients were included, of whom 42 (12.5%) developed cancer after a median of 6.3 years. In univariable analysis, older age at HTx, smoking history, alcohol use, male sex, ischemic heart disease before HTx, use of cyclosporine rather than tacrolimus, and increased length of follow‐up were associated with cancer. Upon multivariable analysis, ischemic heart disease (OR 2.70 [1.19–6.11], p = 0.017) and length of follow‐up (OR 1.02 [1.00–1.04], p = 0.007) were independently associated with cancer occurrence. Cox regression revealed a higher risk of mortality among patients with cancer (HR 3.400, [2.026–5.709], p < 0.001). HTx recipients with prior ischemic cardiomyopathy and a longer survival time after transplant show a higher risk of developing cancer. Cancer significantly impairs post‐transplant survival.